Cytophagic and S‐100 protein immunoreactive myeloid leukemia cutis

Thomas, Crystal G.; Patel, Rajiv M.; Bergfeld, Wilma F.

doi:10.1111/j.1600-0560.2009.01317.x

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients in our cases reports showed a similar clinical presentation to cases documented in the literature. [2,16–19] Gingival hypertrophy is also striking and unique finding of the M4/M5 variants, [1,20] although this feature was not reported in our patients.…”

Section: Discussionmentioning

confidence: 57%

Cutaneous presentation preceding acute monocytic leukemia

Jin

Li²,

Li³

et al. 2017

Medicine

View full text Add to dashboard Cite

Rationale:Cutaneous presentation preceding acute myeloid leukemia (AML) is rare, and the prognosis is poor.Patient concerns:We report 4 cases of AML cutis, where skin infiltration precedes any blood or bone marrow evidence of leukemia. We also reviewed 13 cases reported in English and Chinese literature. The 4 cases all presented typical cutaneous lesions without any systemic evidence of leukemia. Histopathological examination found that dense monomorphous cell infiltration involved the dermis. Some cells surrounded blood vessels and skin appendages in a concentric manner or showed single-row arrangement in the collagen fiber bundles. Uninvolved papillary dermis was found to separate normal epidermis from dermal infiltration. Minor cells had a large kidney-shaped or oval nucleus with nucleoli and slightly eosinophilic cytoplasm. Immunohistochemical analysis was positive for CD4, CD56, while CD123 was negative in all cases.Diagnoses:AML-M5.Interventions:2 patients received chemotherapy ,but others rejected treatment.Outcomes:Most patients died within 1 year after the onset of skin lesions.Lessons:These findings suggest that skin infiltration of AML may precede any systemic evidence, and typical cutaneous lesions in elderly individuals may be indicative for AML.

show abstract

Section: Discussionmentioning

confidence: 57%

Cutaneous presentation preceding acute monocytic leukemia

Jin

Li²,

Li³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…At present, the diagnosis of LC is often made in retrospect once leukemia becomes present clinically. 12 Therefore, it is imperative that clinicians be familiar with features of cutaneous lesions that may indicate an underlying malignancy. 13 A skin biopsy can be the first indication of the presence of leukemia cutis in the patients with systemic leukemia.…”

Section: Discussionmentioning

confidence: 99%

Clinical and pathological features of myeloid leukemia cutis

Wang

Lian

et al. 2018

An. Bras. Dermatol.

View full text Add to dashboard Cite

BackgroundMyeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia.ObjectiveThe purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis.MethodsThis was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis.ResultsOne patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions.Study limitationsThis was a retrospective and small sample study.ConclusionsIn patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings.

show abstract

“…We observed a more than 9-fold differential expression of S100A8 and in the network connecting with RAS, TGFb, MAPK and MMP. The S-100 protein has been previously reported as a useful marker in juvenile chronic myeloid leukemia (JCML) as well as myeloid leukemia cutis (LC) ( 38 , 39 ).…”

Section: Discussionmentioning

confidence: 99%

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients

Alaiya

Aljurf

Shinwari

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

There is unmet need for prediction of treatment response for chronic myeloid leukemia (CML) patients. The present study aims to identify disease-specific/disease-associated protein biomarkers detectable in bone marrow and peripheral blood for objective prediction of individual’s best treatment options and prognostic monitoring of CML patients. Bone marrow plasma (BMP) and peripheral blood plasma (PBP) samples from newly-diagnosed chronic-phase CML patients were subjected to expression-proteomics using quantitative two-dimensional gel electrophoresis (2-DE) and label-free liquid chromatography tandem mass spectrometry (LC-MS/MS). Analysis of 2-DE protein fingerprints preceding therapy commencement accurately predicts 13 individuals that achieved major molecular response (MMR) at 6 months from 12 subjects without MMR (No-MMR). Results were independently validated using LC-MS/MS analysis of BMP and PBP from patients that have more than 24 months followed-up. One hundred and sixty-four and 138 proteins with significant differential expression profiles were identified from PBP and BMP, respectively and only 54 proteins overlap between the two datasets. The protein panels also discriminates accurately patients that stay on imatinib treatment from patients ultimately needing alternative treatment. Among the identified proteins are TYRO3, a member of TAM family of receptor tyrosine kinases (RTKs), the S100A8, and MYC and all of which have been implicated in CML. Our findings indicate analyses of a panel of protein signatures is capable of objective prediction of molecular response and therapy choice for CML patients at diagnosis as ‘personalized-medicine-model’.

show abstract

Cytophagic and S‐100 protein immunoreactive myeloid leukemia cutis

Cited by 7 publications

References 37 publications

Cutaneous presentation preceding acute monocytic leukemia

Cutaneous presentation preceding acute monocytic leukemia

Clinical and pathological features of myeloid leukemia cutis

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients

Contact Info

Product

Resources

About